




Instance: composition-en-9648a8c3d3b260e0c01496efb4b0ef56
InstanceOf: CompositionUvEpi
Title: "Composition for vosevi Package Leaflet"
Description:  "Composition for vosevi Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd6dc10a3838ebc04ecae471e0e2d37dd)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vosevi"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>If Vosevi has been prescribed for your child, please note that all the information in this leaflet is 
addressed to your child (in this case please read  your child  instead of  you ). </p>         </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Vosevi is and what it is used for </li>
<li>What you need to know before you take Vosevi </li>
<li>How to take Vosevi </li>
<li>Possible side effects </li>
<li>How to store Vosevi </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vosevi is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vosevi is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vosevi is a medicine that contains the active substances sofosbuvir, velpatasvir and voxilaprevir in a 
single tablet. It is given to treat a chronic (long-term) viral infection of the liver called hepatitis C in 
patients aged 12 years and older and weighing at least 30 kg. </p>
<p>The active substances in this medicine work together by blocking three different proteins that the 
hepatitis C virus needs to grow and reproduce itself, causing the infection to be eliminated from the 
body. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vosevi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vosevi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Vosevi </p>
<ul>
<li>If you are allergic to sofosbuvir, velpatasvir, voxilaprevir or any of the other ingredients of this 
medicine (listed in section 6 of this leaflet). </li>
</ul>
<p>If this applies to you, do not take Vosevi and tell your doctor immediately. </p>
<ul>
<li>If you are currently taking any of the following medicines: </li>
<li>rifampicin and rifabutin (antibiotics used to treat infections, including tuberculosis); </li>
<li>St. John s wort (Hypericum perforatum) (a herbal medicine used to treat depression); </li>
<li>carbamazepine, phenobarbital and phenytoin (medicines used to treat epilepsy and 
prevent seizures); </li>
<li>rosuvastatin (a medicine used to treat high blood cholesterol or decrease the risk of 
certain cardiovascular events); </li>
<li>dabigatran etexilate (a medicine used to prevent blood clots); </li>
<li>ethinylestradiol containing medicines, including many contraceptives. 
Warnings and precautions </li>
</ul>
<p>Talk to your doctor if you: 
* have liver problems other than from hepatitis C, for instance 
* if you have a current or previous infection with the hepatitis B virus, since your doctor 
may want to monitor you more closely; 
* if you have had a liver transplant. 
* are taking treatment for human immunodeficiency virus (HIV) infection, since your doctor 
may want to monitor you more closely. </p>
<p>Talk to your doctor or pharmacist before taking Vosevi if: 
* you currently take, or have taken in the last few months, the medicine amiodarone to treat 
irregular heartbeats, as it may result in a life-threatening slowing of your heart beat. Your doctor 
may consider alternative treatments if you have taken this medicine. If treatment with Vosevi is 
needed, you may required additional heart monitoring. 
* you have diabetes. You may need closer monitoring of your blood glucose levels and/or 
adjustment of your diabetes medicines after starting Vosevi. Some diabetic patients have 
experienced low sugar levels in the blood (hypoglycaemia) after starting treatment with 
medicines like Vosevi. </p>
<p>Tell your doctor immediately if you currently take, or have taken in the last months, any medicines 
for heart problems and during treatment you experience: 
* slow or irregular heartbeat, or heart rhythm problems; 
* shortness of breath or worsening of existing shortness of breath; 
* chest pain; 
* light-headedness; 
* palpitations; 
* near fainting or fainting. </p>
<p>Blood tests </p>
<p>Your doctor will test your blood before, during and after your treatment with Vosevi. This is so that: 
* Your doctor can decide if you should take Vosevi and for how long; 
* Your doctor can confirm that your treatment has worked and you are free of the hepatitis C 
virus. </p>
<p>Children and adolescents </p>
<p>Do not give this medicine to children under 12 years of age and weighing less than 30 kg. The use of 
Vosevi in these patients has not yet been studied. </p>
<p>Other medicines and Vosevi </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>If you are not sure talk to your doctor or pharmacist. </p>
<p>Some medicines must not be taken with Vosevi. Taking Vosevi with any of these may stop your 
medicines from working properly, or make any side effects worse: 
* rifampicin and rifabutin (antibiotics used to treat infections, including tuberculosis); 
* St. John s wort (Hypericum perforatum) (a herbal medicine used to treat depression); 
* carbamazepine, phenobarbital and phenytoin (medicines used to treat epilepsy and prevent 
seizures); 
* rosuvastatin (a medicine used to treat high blood cholesterol or decrease the risk of certain 
cardiovascular events); 
* dabigatran etexilate (a medicine used to prevent blood clots); 
* ethinylestradiol containing medicines, including many contraceptives. </p>
<p>Tell your doctor or pharmacist if you are taking any of the medicines below: </p>
<ul>
<li>amiodarone, used to treat irregular heartbeats; </li>
<li>rifapentine (an antibiotic used to treat infections, including tuberculosis); </li>
<li>oxcarbazepine (medicine used to treat epilepsy and prevent seizures); </li>
<li>tenofovir disoproxil fumarate, or any medicine containing tenofovir disoproxil fumarate, used 
to treat HIV infection; </li>
<li>atazanavir, efavirenz or lopinavir, used to treat HIV infection; </li>
<li>digoxin, used to treat heart conditions; </li>
<li>modafinil, used to treat sleep disorders; </li>
<li>atorvastatin, pravastatin, or other statins, used to treat high cholesterol; </li>
<li>
<p>ciclosporin, used to suppress the immune system. 
Taking Vosevi with any of these may stop your medicines from working properly, or make any side 
effects worse. Your doctor may need to give you a different medicine or adjust the dose of medicine 
you are taking. </p>
</li>
<li>
<p>Get advice from a doctor or pharmacist if you take medicines used to treat stomach ulcers, 
heartburn or acid reflux as they can decrease the amount of velpatasvir in your blood. These 
medicines include: </p>
</li>
<li>antacids (such as aluminium/magnesium hydroxide or calcium carbonate). These should 
be taken at least 4 hours before or 4 hours after Vosevi; </li>
<li>proton pump inhibitors (such as omeprazole, lansoprazole, rabeprazole, pantoprazole and 
esomeprazole). If you need high doses of these medicines your doctor may give you a 
different medicine instead or adjust the dose of the medicine you are taking; </li>
<li>
<p>H2-receptor antagonists (such as famotidine, cimetidine, nizatidine or ranitidine). If you 
need high doses of these medicines your doctor may give you a different medicine instead 
or adjust the dose of the medicine you are taking. 
These medicines can decrease the amount of Vosevi in your blood. If you are taking one of these 
medicines your doctor will either give you a different medicine for stomach ulcers, heartburn or acid 
reflux, or recommend how and when you take that medicine. </p>
</li>
<li>
<p>Get advice from a doctor or pharmacist if you take warfarin or other similar medicines 
called vitamin K antagonists used to thin the blood. Your doctor may need to increase the 
frequency of your blood tests to check how well your blood can clot. </p>
</li>
<li>Your liver function may change with treatment of hepatitis C and therefore may affect other 
medicines (e.g. medicines used to suppress your immune system, etc.). Your doctor may need to 
closely monitor these other medicines you are taking and make adjustments after starting 
Vosevi. </li>
</ul>
<p>Pregnancy, breast-feeding and fertility </p>
<p>If you are pregnant, think you may be pregnant, are breast-feeding your baby, or are planning to have 
a baby ask your doctor for advice before taking this medicine. </p>
<p>Pregnancy </p>
<p>Vosevi is not recommended during pregnancy. The effects of Vosevi during pregnancy are not 
known. </p>
<p>Breast-feeding </p>
<p>Do not breast-feed during treatment with Vosevi. Some of the active substances of Vosevi may 
pass into human breast milk. </p>
<p>Driving and using machines </p>
<p>Vosevi should not affect your ability to drive or use any tools or machinery. </p>
<p>Vosevi contains lactose </p>
<p>Tell your doctor if you are lactose intolerant or intolerant to other sugars. Vosevi contains lactose 
monohydrate. If you have been told by your doctor that you have an intolerance to some sugars 
contact your doctor before taking this medicine. </p>
<p>Vosevi contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium 
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vosevi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vosevi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>Recommended dose </p>
<p>The recommended dose of Vosevi is one 400 mg/100 mg/100 mg tablet or two 200 mg/50 mg/50 mg 
tablets, taken once a day for 8 or 12 weeks. </p>
<p>Take Vosevi as advised by your doctor. </p>
<p>Swallow the tablet(s) whole with food. Do not chew, crush or split the tablet as it has a very bitter 
taste. </p>
<p>Kidney problems </p>
<p>Tell your doctor if you have kidney problems or if you are on kidney dialysis, since Vosevi has not 
been fully tested in patients with severe kidney problems. </p>
<p>Liver problems </p>
<p>Vosevi should not be used if you have moderate or severe liver problems. </p>
<p>If you are taking an antacid, take it at least 4 hours before or at least 4 hours after Vosevi. </p>
<p>If you are sick (vomit) after taking Vosevi it may affect the amount of Vosevi in your blood. This 
may make Vosevi work less well. 
* If you are sick (vomit) less than 4 hours after taking Vosevi, take another dose. 
* If you are sick (vomit) more than 4 hours after taking Vosevi, you do not need to take another 
dose until your next scheduled dose. </p>
<p>If you take more Vosevi than you should </p>
<p>If you accidentally take more than the recommended dose of Vosevi you may be at increased risk of 
side effects with this medicine (see section 4 Possible side effects). </p>
<p>Contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle 
with you so that you can easily describe what you have taken. </p>
<p>If you forget to take Vosevi </p>
<p>It is important not to miss a dose of this medicine. </p>
<p>If you do miss a dose, work out how long it is since you last took your Vosevi: 
* If you notice within 18 hours of the time you usually take Vosevi, you must take the missed 
dose as soon as possible. Then take the next dose at your usual time. 
* If it is 18 hours or more after the time you usually take Vosevi, wait and take the next dose at 
your usual time. Do not take a double dose (two doses close together) to make up for a forgotten 
dose. </p>
<p>Do not stop taking Vosevi </p>
<p>Do not stop taking this medicine unless your doctor tells you to. It is very important that you complete 
the full course of treatment to give the medicine the best chance to treat your hepatitis C virus 
infection. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine may cause side effects, although not everybody gets them. </p>
<p>Some side effects could be serious </p>
<p>Stop taking Vosevi and seek medical help immediately if you experience any of the following 
symptoms: 
* swelling of the face, lips, tongue or throat (angioedema) (an uncommon side effect - may affect 
up to 1 in 100 people) 
* a wide-spread severe rash with peeling skin which may be accompanied by fever, flu like 
symptoms, blisters in the mouth, eyes, and/or genitals (Stevens Johnson syndrome) (the 
frequency of the side effect is not known) </p>
<p>Other side effects that may occur </p>
<p>Very common side effects 
(may affect more than 1 in 10 people) 
* headache 
* diarrhoea 
* feeling sick (nausea) </p>
<p>Common side effects 
(may affect up to 1 in 10 people) 
* stomach pain 
* decreased appetite 
* being sick (vomiting) 
* muscle pain (myalgia) 
* abnormality in a laboratory test of liver function (total bilirubin) 
* rash </p>
<p>Uncommon side effects 
(may affect up to 1 in 100 people) 
* muscle spasms </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vosevi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vosevi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the bottle and carton after  EXP . 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special temperature storage conditions. Store in the original 
package in order to protect from moisture. Keep the bottle tightly closed. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Vosevi contains </p>
<ul>
<li>
<p>The active substances are sofosbuvir, velpatasvir and voxilaprevir. Each film-coated tablet 
contains 400 mg sofosbuvir, 100 mg velpatasvir and 100 mg voxilaprevir or 200 mg sofosbuvir, 
50 mg velpatasvir and 50 mg voxilaprevir. </p>
</li>
<li>
<p>The other ingredients are 
Tablet core: 
Colloidal anhydrous silica, copovidone, croscarmellose sodium (E468) (see section 2 of this 
leaflet), lactose monohydrate (see section 2 of this leaflet), magnesium stearate, microcrystalline 
cellulose (E460) </p>
</li>
</ul>
<p>Film-coating: 
Iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172), macrogol (E1521), 
polyvinyl alcohol (E1203), talc (E553b), titanium dioxide (E171) </p>
<p>What Vosevi looks like and contents of the pack </p>
<p>Vosevi 400 mg/100 mg/100 mg film-coated tablets are beige, capsule-shaped tablets debossed with 
 GSI  on one side and  3  on the other side. The tablet is 20 mm long and 10 mm wide. </p>
<p>Vosevi 200 mg/50 mg/50 mg film-coated tablets are beige, oval-shaped tablets debossed with  GSI<br />
on one side and  SVV  on the other side. The tablet is 15 mm long and 8 mm wide. </p>
<p>The tablets are packed in plastic bottles with child resistant caps. Each bottle contains a silica gel 
desiccant (drying agent) that must be kept in the bottle to help protect your tablets. The silica gel 
desiccant is contained in a separate sachet or canister and should not be swallowed. </p>
<p>The following pack size is available for both 400 mg/100 mg/100 mg and 200 mg/50 mg/50 mg film-
coated tablets: 
* outer cartons containing 1 bottle of 28 film-coated tablets </p>
<p>Marketing Authorisation Holder 
Gilead Sciences Ireland UC 
Carrigtohill 
County Cork, T45 DPIreland </p>
<p>Manufacturer 
Gilead Sciences Ireland UC 
IDA Business &amp; Technology Park 
Carrigtohill 
County Cork 
Ireland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Gilead Sciences Belgium SRL-BV 
T l/Tel: + 32 (0) 24 01 35 Lietuva 
Gilead Sciences Poland Sp. z o.o. 
Tel: + 48 22 262 8<br />
Gilead Sciences Ireland UC 
 .: + 353 (0) 1 686 1Luxembourg/Luxemburg 
Gilead Sciences Belgium SRL-BV 
T l/Tel: + 32 (0) 24 01 35  esk  republika 
Gilead Sciences s.r.o. 
Tel: + 420 910 871 Magyarorsz g 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1Danmark 
Gilead Sciences Sweden AB 
Tlf: + 46 (0) 8 5057 1Malta 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1Deutschland 
Gilead Sciences GmbH 
Tel: + 49 (0) 89 899890-0 </p>
<p>Nederland 
Gilead Sciences Netherlands B.V. 
Tel: + 31 (0) 20 718 36 Eesti 
Gilead Sciences Poland Sp. z o.o. 
Tel: + 48 22 262 8Norge 
Gilead Sciences Sweden AB 
Tlf: + 46 (0) 8 5057 1<br />
Gilead Sciences    . . 
 : + 30 210 8930  sterreich 
Gilead Sciences GesmbH 
Tel: + 43 1 260 Espa a 
Gilead Sciences, S.L. 
Tel: + 34 91 378 98 Polska 
Gilead Sciences Poland Sp. z o.o. 
Tel: + 48 22 262 8France 
Gilead Sciences 
T l: + 33 (0) 1 46 09 41 Portugal 
Gilead Sciences, Lda. 
Tel: + 351 21 7928Hrvatska 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1Rom nia 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1Ireland 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 214 825 Slovenija 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 sland 
Gilead Sciences Sweden AB 
S mi: + 46 (0) 8 5057 1Slovensk  republika 
Gilead Sciences Slovakia s.r.o. 
Tel: + 421 232 121 Italia 
Gilead Sciences S.r.l. 
Tel: + 39 02 439Suomi/Finland 
Gilead Sciences Sweden AB 
Puh/Tel: + 46 (0) 8 5057 1<br />
Gilead Sciences    . . 
 : + 30 210 8930 Sverige 
Gilead Sciences Sweden AB 
Tel: + 46 (0) 8 5057 1Latvija 
Gilead Sciences Poland Sp. z o.o. 
Tel: + 48 22 262 8United Kingdom (Northern Ireland) 
Gilead Sciences Ireland UC 
Tel: + 44 (0) 8000 113 This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-9648a8c3d3b260e0c01496efb4b0ef56
InstanceOf: CompositionUvEpi
Title: "Composition for vosevi Package Leaflet"
Description:  "Composition for vosevi Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd6dc10a3838ebc04ecae471e0e2d37dd)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vosevi"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvis Vosevi er blevet ordineret til dit barn, skal du være opmærksom på, at alle oplysningerne i 
denne indlægsseddel vedrører dit barn (hvis det er tilfældet skal du læse "dit barn" i stedet for 
"du"). </p>         </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Vosevi </li>
<li>Sådan skal du tage Vosevi </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vosevi is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vosevi is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vosevi er et lægemiddel, der indeholder de aktive stoffer sofosbuvir, velpatasvir og voxilaprevir i den 
samme tablet. Det gives til behandling af patienter i alderen 12 år og derover, og som vejer mindst kg, med en kronisk (langvarig) virusinfektion i leveren, der kaldes hepatitis C. </p>
<p>De aktive stoffer i dette lægemiddel arbejder sammen ved at blokere tre forskellige proteiner, som 
hepatitis C-virusset skal bruge til at vokse og formere sig, og forårsager derved at infektionen 
udryddes i kroppen. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vosevi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vosevi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Vosevi </p>
<ul>
<li>Hvis du er allergisk over for sofosbuvir, velpatasvir, voxilaprevir eller et af de øvrige 
indholdsstoffer i Vosevi (angivet i punkt 6). </li>
</ul>
<p> Hvis dette gælder for dig, må du ikke tage Vosevi, og du skal straks fortælle det til lægen. </p>
<ul>
<li>
<p>Hvis du aktuelt tager nogle af de følgende lægemidler: </p>
</li>
<li>
<p>rifampicin og rifabutin (antibiotika, der anvendes til behandling af infektioner, herunder 
tuberkulose) </p>
</li>
<li>
<p>perikon (Hypericum perforatum) (et naturlægemiddel, der anvendes mod depression) </p>
</li>
<li>
<p>carbamazepin, phenobarbital og phenytoin (medicin, der anvendes til at behandle 
epilepsi og forebygge krampeanfald) </p>
</li>
<li>
<p>rosuvastatin (medicin, der anvendes til at behandle forhøjet blodkolesterol eller nedsætte 
risikoen for visse hjerte/karhændelser) </p>
</li>
<li>
<p>dabigatranetexilat (medicin, der anvendes til at forebygge blodpropper) </p>
</li>
<li>
<p>ethinylestradiol-indeholdende lægemidler, herunder mange kontraceptiva </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Tal med din læge, hvis du: </p>
<ul>
<li>
<p>har andre leverproblemer end hepatitis C, for eksempel </p>
</li>
<li>
<p>hvis du har eller tidligere har haft en infektion med hepatitis B-virussen, da din læge 
kan ønske at overvåge dig nøjere </p>
</li>
<li>
<p>hvis du har gennemgået en levertransplantation </p>
</li>
<li>
<p>er i behandling for hiv-infektion, da din læge kan ønske at overvåge dig nøjere. </p>
</li>
</ul>
<p>Kontakt lægen eller apotekspersonalet, før du tager Vosevi, hvis: </p>
<ul>
<li>
<p>du får eller inden for de seneste par måneder har fået lægemidlet amiodaron mod uregelmæssig 
hjerterytme, da det kan medføre en livstruende reduktion af din puls. Lægen kan overveje andre 
behandlinger, hvis du har taget dette lægemiddel. Hvis behandling med Vosevi er nødvendig, 
kan yderligere overvågning af dit hjerte være nødvendig. </p>
</li>
<li>
<p>du har diabetes. Det kan være, at dit blodsukker skal overvåges tættere, og/eller at din 
diabetesmedicin skal justeres efter påbegyndelse af behandling med Vosevi. Nogle patienter 
med diabetes har oplevet lavt blodsukker (hypoglykæmi) efter påbegyndelse af behandling med 
lægemidler som Vosevi. </p>
</li>
</ul>
<p>Sig det straks til lægen, hvis du aktuelt tager, eller i den seneste måned har taget et hvilket som helst 
lægemiddel mod hjerteproblemer, og du under behandlingen oplever: </p>
<ul>
<li>
<p>langsom eller uregelmæssig puls, eller hjerterytmeproblemer </p>
</li>
<li>
<p>åndenød eller forværring af eksisternede åndenød </p>
</li>
<li>
<p>brystsmerter </p>
</li>
<li>
<p>svimmelhed </p>
</li>
<li>
<p>hjertebanken </p>
</li>
<li>
<p>at du er tæt på at besvime eller få besvimelsesanfald </p>
</li>
</ul>
<p>Blodprøver </p>
<p>Din læge vil undersøge dit blod før, under og efter din behandling med Vosevi. Dette gøres så: </p>
<ul>
<li>
<p>Din læge kan beslutte, om du skal tage Vosevi og hvor længe </p>
</li>
<li>
<p>Din læge kan bekræfte, at behandlingen har virket, og at du ikke længere har hepatitis C-virus. </p>
</li>
</ul>
<p>Børn og unge </p>
<p>Giv ikke dette lægemiddel til børn under 12 år, og som vejer mindre end 30 kg. Anvendelsen af 
Vosevi er endnu ikke undersøgt hos disse patienter. </p>
<p>Brug af anden medicin sammen med Vosevi </p>
<p>Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden 
medicin eller planlægger at tage anden medicin.  </p>
<p>Er du i tvivl, så tal med lægen eller apotekspersonalet. </p>
<p>Nogle lægemidler må ikke tages sammen med Vosevi. At tage Vosevi med nogen af disse kan 
stoppe din medicin med at virke korrekt, eller forværre bivirkningerne: </p>
<ul>
<li>
<p>rifampicin og rifabutin (antibiotika, der anvendes til behandling af infektioner, herunder 
tuberkulose) </p>
</li>
<li>
<p>perikon (Hypericum perforatum) (et naturlægemiddel, der anvendes mod depression) </p>
</li>
<li>
<p>carbamazepin, phenobarbital og phenytoin (medicin, der anvendes til at behandle epilepsi og 
forebygge krampeanfald) </p>
</li>
<li>
<p>rosuvastatin (medicin, der anvendes til at behandle forhøjet blodkolesterol eller nedsætte 
risikoen for visse hjerte/karhændelser) </p>
</li>
<li>
<p>dabigatranetexilat (medicin, der anvendes til at forebygge blodpropper) </p>
</li>
<li>
<p>ethinylestradiol-indeholdende lægemidler, herunder mange kontraceptiva </p>
</li>
</ul>
<p>Fortæl altid lægen eller apotekspersonalet, hvis du tager nogle af følgende lægemidler: </p>
<ul>
<li>
<p>amiodaron, som anvendes til behandling af uregelmæssig hjerterytme </p>
</li>
<li>
<p>rifapentin (et antibiotikum, der anvendes til behandling af infektioner, herunder tuberkulose) </p>
</li>
<li>
<p>oxcarbazepin (lægemiddel der anvendes til at behandle epilepsi og forebygge krampeanfald) </p>
</li>
<li>
<p>tenofovirdisoproxilfumarat eller et hvilket som helst lægemiddel, der indeholder 
tenofovirdisoproxilfumarat, (lægemiddel der anvendes til at behandle hiv-infektion) </p>
</li>
<li>
<p>atazanavir, efavirenz eller lopinavir, som anvendes til at behandle hiv-infektion </p>
</li>
<li>
<p>digoxin, som anvendes til at behandle hjertesygdomme </p>
</li>
<li>
<p>modafinil, som anvendes til at behandle søvnforstyrrelser </p>
</li>
<li>
<p>atorvastatin, pravastatin eller andre statiner, der anvendes til at behandle forhøjet kolesterol </p>
</li>
<li>
<p>ciclosporin, der anvendes til suppression af immunssystemet 
Hvis du tager Vosevi sammen med nogle af disse lægemidler, kan det forhindre, at lægemidlerne 
virker korrekt, eller det kan gøre bivirkninger mere udtalte. Det kan være nødvendigt, at din læge giver 
dig et andet lægemiddel, eller justerer dosis af det lægemiddel, du tager.  </p>
</li>
<li>
<p>Få rådgivning fra en læge eller apotekspersonalet, hvis du tager lægemidler, der anvendes til 
at behandle mavesår, halsbrand eller sure opstød, da disse kan nedsætte mængden af 
velpatasvir i blodet. Disse lægemidler omfatter: </p>
</li>
<li>
<p>syreneutraliserede midler (såsom aluminium/magnesiumhydroxid eller calciumcarbonat). 
Disse lægemidler skal tages mindst 4 timer før eller 4 timer efter Vosevi. </p>
</li>
<li>
<p>protonpumpehæmmere (såsom omeprazol, lansoprazol, rabeprazol, pantoprazol og 
esomeprazol). Hvis du behøver høje doser af disse lægemidler, vil din læge muligvis give 
dig et andet lægemiddel i stedet eller justere dosen af din medicin. </p>
</li>
<li>
<p>H2-receptorantagonister (såsom famotidin, cimetidin, nizatidin eller ranitidin). Hvis du 
har behov for høje doser af disse lægemidler, kan din læge give dig et andet lægemiddel i 
stedet eller justere dosis af det lægemiddel, du tager. 
Disse lægemidler kan nedsætte mængden af Vosevi i blodet. Hvis du tager et af disse lægemidler, vil 
din læge enten give dig et andet lægemiddel mod mavesår, halsbrand eller sure opstød, eller anbefale, 
hvordan og hvornår du tager lægemidlet. </p>
</li>
<li>
<p>Få rådgivning fra en læge eller apotekspersonalet, hvis du tager warfarin eller andre 
lignende lægemidler, såkaldte vitamin K-antagonister, der anvendes til fortynding af blodet. 
Din læge kan være nødt til at tage hyppigere blodprøver for at kontrollere, hvor godt dit blod 
størkner. </p>
</li>
<li>
<p>Din leverfunktion kan ændre sig under behandling for hepatitis C, og kan derfor påvirke anden 
medicin (f.eks. medicin brugt til at undertrykke dit immunsystem osv.). Lægen kan være nødt til 
nøje at overvåge disse andre lægemidler, som du tager, og foretage dosisjusteringer efter 
påbegyndelse af Vosevi. </p>
</li>
</ul>
<p>Graviditet, amning og frugtbarhed </p>
<p>Hvis du er gravid, har mistanke om, at du er gravid, ammer, eller planlægger at blive gravid, skal du 
spørge din læge til råds, før du tager dette lægemiddel. Virkningerne af Vosevi på graviditet kendes 
ikke. </p>
<p>Graviditet </p>
<p>Vosevi frarådes under graviditet. Virkningen af Vosevi under graviditet er ikke klarlagt. </p>
<p>Amning </p>
<p>Du må ikke amme under behandlingen med Vosevi. Nogle aktive stoffer i Vosevi, kan udskilles i 
modermælken hos mennesker. </p>
<p>Trafik- og arbejdssikkerhed </p>
<p>Vosevi vil ikke påvirke din evne til at føre køretøjer eller anvende værktøj eller maskiner. </p>
<p>Vosevi indeholder lactose </p>
<p>Fortæl lægen, hvis du er intolerant over for lactose eller ikke tåler andre sukkerarter.  Kontakt 
lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter. </p>
<p>Vosevi indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vosevi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vosevi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Anbefalet dosis </p>
<p>Den anbefalede dosis Vosevi er én 400 mg/100 mg/100 mg tablet eller to 200 mg/50 mg/50 mg 
tabletter én gang om dagen i 8 eller 12 uger. </p>
<p>Tag Vosevi som anvist af lægen. </p>
<p>Slug tabletten/tabletterne hel med mad. Tabletten må ikke tygges, knuses eller deles, da den har en 
meget bitter smag. </p>
<p>Nyreproblemer </p>
<p>Fortæl lægen, hvis du har nyreproblemer, eller hvis du får dialyse, da Vosevi ikke er blevet fuldt 
undersøgt hos patienter med svære nyreproblemer. </p>
<p>Leverproblemer </p>
<p>Vosevi bør ikke anvendes, hvis du har moderate eller alvorlige leverproblemer. </p>
<p>Hvis du tager et syreneutraliserende middel, skal du tage det mindst 4 timer før eller mindst 4 timer 
efter Vosevi. </p>
<p>Hvis du kaster op, efter du har taget Vosevi, kan det påvirke mængden af Vosevi i blodet. Dette kan 
få Vosevi til at virke mindre effektivt. </p>
<ul>
<li>
<p>Hvis du kaster op mindre end 4 timer efter, du har taget Vosevi, skal du tage en ny dosis. </p>
</li>
<li>
<p>Hvis du kaster op mere end 4 timer efter, du har taget Vosevi, skal du ikke tage en anden dosis 
før din næste skemalagte dosis. </p>
</li>
</ul>
<p>Hvis du har taget for meget Vosevi </p>
<p>Hvis du utilsigtet har taget mere end den anbefalede dosis Vosevi, kan du have større risiko for at få 
bivirkninger af lægemidlet (se punkt 4, Bivirkninger).  </p>
<p>Kontakt straks lægen eller den nærmeste skadestue for rådgivning. Tag tabletbeholderen med, så du let 
kan beskrive, hvad du har taget. </p>
<p>Hvis du har glemt at tage Vosevi </p>
<p>Det er vigtigt ikke at glemme en dosis af dette lægemiddel. </p>
<p>Hvis du glemmer en dosis, skal du regne ud, hvor lang tid der er gået, siden du sidst tog Vosevi: </p>
<ul>
<li>
<p>Hvis du opdager det inden for 18 timer efter det tidspunkt, du normalt tager Vosevi, skal du 
tage den glemte dosis snarest muligt. Tag dernæst den næste dosis til sædvanlig tid. </p>
</li>
<li>
<p>Hvis det er 18 timer eller længere efter det tidspunkt, du normalt tager Vosevi, skal du vente 
og tage den næste dosis på det sædvanlige tidspunkt. Du må ikke tage en dobbeltdosis (to doser 
tæt på hinanden), som erstating for den glemte dosis. </p>
</li>
</ul>
<p>Du må ikke holde op med at tage Vosevi </p>
<p>Du må ikke holde op med at tage dette lægemiddel, medmindre lægen fortæller dig det. Det er meget 
vigtigt, at du gennemfører hele behandlingsprogrammet, så lægemidlet får de bedste betingelser for at 
behandle din infektion med hepatitis C. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Nogle bivirkninger kan være alvorlige </p>
<p>Stop med at tage Vosevi og søg straks lægehjælp, hvis du oplever nogen af følgende symptomer: </p>
<ul>
<li>
<p>hævelse af ansigt, læber, tunge eller hals (angioødem) (en ikke almindelig bivirkning – kan 
påvirke op til 1 ud af 100 personer) </p>
</li>
<li>
<p>et udbredt, alvorligt udslæt, hvor huden skaller af, og som kan være ledsaget af feber, 
influenzalignende symptomer, blærer i munden, øjnene og/eller på kønsorganerne 
(Stevens-Johnson syndrom) (hyppigheden af bivirkningen er ikke kendt) </p>
</li>
</ul>
<p>Andre bivirkninger, der kan forekomme </p>
<p>Meget almindelige bivirkninger 
(kan påvirke mere end 1 ud af 10 personer) </p>
<ul>
<li>
<p>hovedpine </p>
</li>
<li>
<p>diarré </p>
</li>
<li>
<p>føle sig dårlig (kvalme) </p>
</li>
</ul>
<p>Almindelige bivirkninger 
(kan påvirke op til 1 ud af 10 personer) </p>
<ul>
<li>
<p>mavesmerter </p>
</li>
<li>
<p>mindsket appetit </p>
</li>
<li>
<p>opkastning </p>
</li>
<li>
<p>muskelsmerter (myalgi) </p>
</li>
<li>
<p>unormalitet i laboratorieundersøgelser af leverfunktion (total bilirubin) </p>
</li>
<li>
<p>udslæt </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger 
(kan påvirke op til 1 i 100 personer) </p>
<ul>
<li>muskelspasmer </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vosevi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vosevi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på tabletbeholderen og kartonen efter "EXP". 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Der er ingen særlige krav vedrørende opbevaringstemperaturer for dette lægemiddel. Opbevares i den 
originale yderpakning for at beskytte mod fugt. Hold beholderen tæt tillukket. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vosevi indeholder: </p>
<ul>
<li>
<p>Aktive stoffer: sofosbuvir, velpatasvir og voxilaprevir. Hver filmovertrukket tablet indeholder 
400 mg sofosbuvir, 100 mg velpatasvir og 100 mg voxilaprevir eller 200 mg sofosbuvir, 50 mg 
velpatasvir og 50 mg voxilaprevir. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: 
Tabletkerne: 
Vandfrit siliciumdioxid, copovidon, croscarmellosenatrium (E468) (se punkt 2 i denne 
indlægsseddel), lactosemonohydrat (se punkt 2 i denne indlægsseddel), magnesiumstearat, 
mikrokrystallinsk cellulose (E460) </p>
</li>
</ul>
<p>Filmovertræk: 
Sort jernoxid (E172), rød jernoxid (E172), gul jernoxid (E172), macrogol (E1521), 
polyvinylalkohol (E1203), talcum (E553b), titandioxid (E171). </p>
<p>Udseende og pakningsstørrelser </p>
<p>Vosevi 400 mg/100 mg/100 mg filmovertrukne tabletter er beige, kapselformede tabletter, præget med 
"GSI" på den ene side og med "3" på den anden side. Tabletten er 20 mm lang og 10 mm bred. </p>
<p>Vosevi 200 mg/50 mg/50 mg filmovertrukne tabletter er beige, ovale tabletter, præget med "GSI" på 
den ene side og "SVV" på den anden side. Tabletten er 15 mm lang og 8 mm bred. </p>
<p>Tabletterne er pakket i plastbeholdere med børnesikret låg. Hver beholder indeholder et silicagel-
tørremiddel, som skal blive i beholderen for at hjælpe med at beskytte tabletterne. Silicagel-
tørremidlet kommer i et separat brev eller hylster og må ikke sluges. </p>
<p>Følgende pakningsstørrelse er tilgængelig for både 400 mg/100 mg/100 mg og 200 mg/50 mg/50 mg 
filmovertrukne tabletter: </p>
<ul>
<li>æske indeholdende 1 tabletbeholder med 28 filmovertrukne tabletter </li>
</ul>
<p>Indehaver af markedsføringstilladelsen<br />
Gilead Sciences Ireland UC 
Carrigtohill 
County Cork, T45 DPIrland </p>
<p>Fremstiller 
Gilead Sciences Ireland UC 
IDA Business &amp; Technology Park 
Carrigtohill 
County Cork 
Irland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Gilead Sciences Belgium SRL-BV 
Tél/Tel: + 32 (0) 24 01 35<br />
Lietuva 
Gilead Sciences Poland Sp. z o.o. 
Tel: + 48 22 262 8 
България 
Gilead Sciences Ireland UC 
Тел.: + 353 (0) 1 686 1 
Luxembourg/Luxemburg 
Gilead Sciences Belgium SRL-BV 
Tél/Tel: + 32 (0) 24 01 35<br />
Česká republika 
Gilead Sciences s.r.o. 
Tel: + 420 910 871<br />
Magyarország 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 
Danmark 
Gilead Sciences Sweden AB 
Tlf: + 46 (0) 8 5057 1 
Malta 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 
Deutschland 
Gilead Sciences GmbH 
Tel: + 49 (0) 89 899890-0 </p>
<p>Nederland 
Gilead Sciences Netherlands B.V. 
Tel: + 31 (0) 20 718 36<br />
Eesti 
Gilead Sciences Poland Sp. z o.o. 
Tel: + 48 22 262 8 
Norge 
Gilead Sciences Sweden AB 
Tlf: + 46 (0) 8 5057 1 
Ελλάδα 
Gilead Sciences Ελλάς Μ.ΕΠΕ. 
Τηλ: + 30 210 8930<br />
Österreich 
Gilead Sciences GesmbH 
Tel: + 43 1 260<br />
España 
Gilead Sciences, S.L. 
Tel: + 34 91 378 98<br />
Polska 
Gilead Sciences Poland Sp. z o.o. 
Tel: + 48 22 262 8 
France 
Gilead Sciences 
Tél: + 33 (0) 1 46 09 41<br />
Portugal 
Gilead Sciences, Lda. 
Tel: + 351 21 7928 
Hrvatska 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 
România 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 
Ireland 
Gilead Sciences Ireland UC 
Tel: +353 (0) 214 825<br />
Slovenija 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 
Ísland 
Gilead Sciences Sweden AB 
Sími: + 46 (0) 8 5057 1 
Slovenská republika 
Gilead Sciences Slovakia s.r.o. 
Tel: + 421 232 121<br />
Italia 
Gilead Sciences S.r.l. 
Tel: + 39 02 439 
Suomi/Finland 
Gilead Sciences Sweden AB 
Puh/Tel: + 46 (0) 8 5057 1 
Κύπρος 
Gilead Sciences Ελλάς Μ.ΕΠΕ. 
Τηλ: + 30 210 8930<br />
Sverige 
Gilead Sciences Sweden AB 
Tel: + 46 (0) 8 5057 1 
Latvija 
Gilead Sciences Poland Sp. z o.o. 
Tel: + 48 22 262 8 
United Kingdom (Northern Ireland) 
Gilead Sciences Ireland UC 
Tel: + 44 (0) 8000 113  </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-9648a8c3d3b260e0c01496efb4b0ef56
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vosevi Package Leaflet for language en"
Description: "ePI document Bundle for vosevi Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-9648a8c3d3b260e0c01496efb4b0ef56"
* entry[0].resource = composition-en-9648a8c3d3b260e0c01496efb4b0ef56

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9648a8c3d3b260e0c01496efb4b0ef56"
* entry[=].resource = mp9648a8c3d3b260e0c01496efb4b0ef56
                            
                    
Instance: bundlepackageleaflet-da-9648a8c3d3b260e0c01496efb4b0ef56
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vosevi Package Leaflet for language da"
Description: "ePI document Bundle for vosevi Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-9648a8c3d3b260e0c01496efb4b0ef56"
* entry[0].resource = composition-da-9648a8c3d3b260e0c01496efb4b0ef56

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9648a8c3d3b260e0c01496efb4b0ef56"
* entry[=].resource = mp9648a8c3d3b260e0c01496efb4b0ef56
                            
                    



Instance: mp9648a8c3d3b260e0c01496efb4b0ef56
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product vosevi"
Description: "vosevi"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/17/1223/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "vosevi"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 9648a8c3d3b260e0c01496efb4b0ef56ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "vosevi"

* status = #current
* mode = #working

* title = "List of all ePIs associated with vosevi"

* subject = Reference(mpd6dc10a3838ebc04ecae471e0e2d37dd)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#vosevi "vosevi"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-9648a8c3d3b260e0c01496efb4b0ef56) // vosevi en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-9648a8c3d3b260e0c01496efb4b0ef56) // vosevi da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-9648a8c3d3b260e0c01496efb4b0ef56
InstanceOf: List

* insert 9648a8c3d3b260e0c01496efb4b0ef56ListRuleset
    